By ANDY OBER
Assistant Managing Editor
INDIANAPOLIS — The U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency.
Lilly says Synjardy is the third product containing the medicine epagliflozin to be approved by the FDA, after Jardiance and Glyxambi. The company says Synjardi helps control blood glucose in type 2 diabetes patients. The approval is based on results from multiple clinical trials.
The companies say Synjardy is the fifth medicine developed through the alliance to be approved by the FDA. Boehringer Ingelheim Chief Executive Officer Paul Fonteyne says the partnership has resulted in a “diverse portfolio of treatments that can help patients throughout their diabetes journey.”